Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

"I am excited to join Rigel as it continues to advance its development pipeline," said Dr. Frohlich. "I believe the IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients ...

We continue to evaluate R289, our dual IRAK1/4 inhibitor in an ongoing Phase Ib study in patients with lower-risk MDS. We presented encouraging initial safety and efficacy data from that study at ...

"I believe the IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients with lower-risk myelodysplastic syndrome and glioma, respectively. I look forward to ...

Last month, the FDA granted Orphan Drug designation to R289, Rigel's potent and selective dual inhibitor of IRAK1 and IRAK4, for the treatment of myelodysplastic syndromes (MDS). RIGL is ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript March 4, 2025 Rigel Pharmaceuticals, Inc. beats ...

Sobi said the selective JAK2, IRAK1, and ACRV1 inhibitor will slot into its haematology portfolio alongside Doptelet (avatrombopag), an oral thrombopoietin receptor agonist for primary chronic ...

Commercial strength continued in the fourth quarter for all products with record bottles shipped to patients and clinics and total bottles sold. The following table summarizes total bottles ...